This finding suggests that VEGF inhibitors including bevacizumab may not have as important a role in tumor vascularization as thought previously and raises the possibility that pneumothorax, in addition to other adverse effects of these agents, may be a result of an alternative effect rather than a direct anti-angiogenic effect. The gene discussed is VEGFA; the disease is pneumothorax.